A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.

Abstract

Fluoropyrimidine plus platinum (FP)-based chemotherapy has been widely used as a first-line regimen for advanced or recurrent esophageal cancer, and taxanes have shown efficacy after FP-based chemotherapy, but there is no standard regimen for second-line chemotherapy (SLC). We retrospectively investigated the clinical features of taxane therapy in SLC for esophageal squamous cell carcinoma (ESCC). The selection criteria were pathologically proven ESCC; advanced or recurrent disease previously treated with FP at our hospital; performance status (PS) 0-2; and adequate organ function. Docetaxel (DTX) was administered 3-weekly at 70mg/m(2). Paclitaxel (PTX) was administered at 100mg/m(2) weekly for 6weeks, with 1week's rest. The analysis covered 163 patients from August 2006 to June 2012. Median age was 64years (range 37-83: DTX group 132 patients and PTX group 31). Progression-free survival and median overall survival (OS) were 2.3 and 6.1months, respectively, with PTX and 2.3 and 5.3months with DTX. Response rates were 20.7% for PTX and 5.9% for DTX. The rate of grades 3-4 neutropenia was higher with DTX (32.6%) than with PTX (16.1%). Grade 3 febrile neutropenia was seen in 6.1% of DTX recipients but in no PTX group. According to multivariate analyses of OS, PS 2, number of metastatic sites ≧2, and CRP ≧1mg/dL were independent predictors of poor prognosis. PTX and DTX were both effective in SLC for ESCC, but their toxicity profiles differed. In terms of febrile neutropenia, PTX seems more appropriate.